

Weekly Influenza and COVID-19 Surveillance graphs

UKHSA publishes a weekly national influenza and COVID-19 surveillance report which summaries the information from the surveillance systems which are used to monitor influenza, COVID-19 and other seasonal respiratory viruses in England.

Additional figures based on these surveillance systems are included in this slide set.

The figures presented in this slide set are based on data from week 22 (between 30 May and 05 June 2022).




Contents


- 1) <u>COVID-19 Pandemic Overview</u>
- 2) <u>Confirmed COVID-19 episodes in England</u>
- 3) <u>Respiratory Datamart system (England)</u>
- 4) <u>Second generation surveillance system (SGSS)</u>
- 5) <u>Community surveillance</u>
- 6) <u>Surveillance in 'educational-age' cohorts</u>
- 7) <u>Secondary Care surveillance</u>
- 8) Mortality surveillance
- 9) Possible reinfections in England
- 10) <u>Co/secondary infections with COVID-19</u>




COVID-19 Pandemic Overview

Confirmed COVID-19 episodes tested under Pillar 1, by sample week, since week UK Health 5 2020 Security Agency










Number of deaths since week 10 2020 by week of death and time since laboratory confirmation of COVID-19, England



Since 1 April 2022, free universal symptomatic and asymptomatic testing for the general public in England is no longer available, as outlined in the plan for living with COVID-19. Data should be interpreted in the context of this change to testing.



Confirmed COVID-19 episodes in England




Confirmed COVID-19 episodes in England

Data Information


- From the week 32 report onwards, case rates have been updated to use the latest ONS population estimates for mid-2020. Previously case rates were calculated using the mid-2019 population estimates
- From 11 January 2022 the requirement for <u>confirmatory PCR testing in individuals who test positive using a lateral flow device was</u> <u>temporarily removed</u>.
- Rates by ethnicity and IMD quantile will continue to be presented using the mid-2019 estimates, until the mid-2020 estimates become available.
- From 31 January 2022, UKHSA moved all COVID-19 case reporting in England to use a new episode-based definition which includes
 possible reinfections. Each infection episode is counted separately if there are at least 91 days between positive test results (PCR or
 LFD). Each infection episode begins with the earliest positive specimen date. Further information can be found on the UK COVID-19
 dashboard.
- Since 1 April 2022, free universal symptomatic and asymptomatic testing for the general public in England is no longer available, as
 outlined in the plan for living with COVID-19. As such, there will be a reduction in the reporting of data obtained through Pillar 2 from
 April 2022 onwards. Data in this report should be interpreted in the context of this change to testing. Public health guidance remains in
 place for cases and their close contacts



Confirmed COVID-19 episodes tested under Pillar 2, based on sample week with overall weekly PCR positivity for Pillar 2 (%)




UK Health Weekly confirmed COVID-19 case rates per 100,000, by episode, tested under Security Pillar 2, by sex Agency






UK Health Weekly confirmed COVID-19 case rates per 100,000, by episode, tested under Security Pillar 2, by age group Agency






Weekly PCR positivity (%) of confirmed COVID-19 cases tested overall and by sex under Pillar 2






UK Health Security Agency Weekly PCR positivity (%) of confirmed COVID-19 cases tested under Pillar 2, by male and age group






Weekly PCR positivity (%) of confirmed COVID-19 cases tested under Pillar 2, by female and age group



Please note that due to a technical issue, positivity data was unavailable for the week 21 report.





Weekly confirmed COVID-19 case rates by episode, per 100,000 population (Pillar 2), by UKHSA Centres and sample week






Weekly PCR positivity of confirmed COVID-19 cases tested under Pillar 2 (%) by UKHSA Centres and sample week







Weekly COVID-19 episodes tested under Pillar 1, per 100,000 population by age group and region, weeks 13 to 22



Weekly COVID-19 episodes tested under Pillar 2, per 100,000 population by age group and region, weeks 13 to 22



Weekly COVID-19 episodes tested under Pillar 1, per 100,000 population by ethnicity and region, weeks 13 to 22




14 June 2022

Other ethnic group

—White

Pakistani (Asian or British)


Weekly COVID-19 episodes tested under Pillar 2 per 100,000 population by ethnicity and region, weeks 13 to 22



14 June 2022




Weekly COVID-19 rate tested under Pillar 1, per 100,000 population by IMD quintile (1 being the most deprived and 5 being the least deprived)



*these incidence rates have been calculated using the mid-2019 ONS population estimates




Weekly COVID-19 rate tested under Pillar 2, per 100,000 population by IMD quintile (1 being the most deprived and 5 being the least deprived)



Week Number




Weekly rate of COVID-19 episodes per 100,000 population (Pillar 2), by upper-tier local authority, England (box shows enlarged map of London area)






Cumulative rate of COVID-19 episodes per 100,000 population tested under Pillar 1, by upper-tier local authority, England (box shows enlarged map of London area)





Cumulative rate of COVID-19 episodes per 100,000 population tested under Pillar 2, by upper-tier local authority, England (box shows enlarged map of London area)






Respiratory Datamart system (England)




Respiratory DataMart – Influenza subtypes



Respiratory DataMart – Respiratory syncytial virus (RSV)


UK Health Security Agency





Agency


Respiratory DataMart – Respiratory syncytial virus (RSV) weekly positivity by UKHSA region



```
WK Health
Security
```

Agency


Respiratory DataMart – other respiratory viruses





Second generation surveillance system (SGSS)


SGSS reported Influenza A cases by region (all ages)



The presented figures are based on laboratory reports through SGSS. Testing and reporting procedures vary by virus, UKHSA Centre and over time, including short-term trends in testing. Therefore comparisons should be done with caution. Previously, this data was presented by report date however is now presented by specimen date.

14 June 2022

SGSS reported Influenza B cases by region (all ages)




The presented figures are based on laboratory reports through SGSS. Testing and reporting procedures vary by virus, UKHSA Centre and over time, including short-term trends in testing. Therefore comparisons should be done with caution. Previously, this data was presented by report date however is now presented by specimen date.

14 June 2022




SGSS reported RSV cases by region (all ages)



The presented figures are based on laboratory reports through SGSS. Testing and reporting procedures vary by virus, UKHSA Centre and over time, including short-term trends in testing. Therefore comparisons should be done with caution. Previously, this data was presented by report date however is now presented by specimen date.

SGSS reported Adenovirus cases by region (all ages)




The presented figures are based on laboratory reports through SGSS. Testing and reporting procedures vary by virus, UKHSA Centre and over time, including short-term trends in testing. Therefore comparisons should be done with caution.

Ø\$

UK Health

Security

SGSS reported Parainfluenza cases by region (all ages)



The presented figures are based on laboratory reports through SGSS. Testing and reporting procedures vary by virus, UKHSA Centre and over time, including short-term trends in testing. Therefore comparisons should be done with caution.


Ś

UK Health

Security

UK Health Security Agency


SGSS reported Rhinovirus cases by region (all ages)



The presented figures are based on laboratory reports through SGSS. Testing and reporting procedures vary by virus, UKHSA Centre and over time, including short-term trends in testing. Therefore comparisons should be done with caution.

UK Health Security Agency

SGSS reported hMPV cases by region (all ages)



The presented figures are based on laboratory reports through SGSS. Testing and reporting procedures vary by virus, UKHSA Centre and over time, including short-term trends in testing. Therefore comparisons should be done with caution.



Community surveillance




Acute respiratory infection (ARI) outbreaks linked to educational settings

Data Information

- we report on new acute respiratory infection (ARI) incidents reported to Health Protection Teams (HPTs) and entered on HPZone in the previous reporting week in educational settings by locality
- the incidents captured on HPZone represent a subset of all ongoing clusters and outbreaks in England. A variety of arrangements are in place with local authorities and other stakeholders supporting HPTs, however data may not routinely be documented on HPZone. As a result, the number of outbreaks reported for some of the regions are underestimates

	Number of acute respiratory infection outbreaks reported to UKHSA by type of
UK Health	educational setting, England
Security	
Agency	





Number of acute respiratory infection outbreaks by type of educational setting, England

End of academic year total Week 36 2020- 34 2021

	Cumulative number of confirmed COVID-19 clusters or outbreaks by type of educational setting for the 2020/21 academic year Week 36 2020- 34 2021									
Centres	Nursery	Primary School	Secondary School	Combined	Special Educational Needs (SEN) schools	College University	Total			
Total	846	2125	2122	40	666	268	6067			

Week 22 2022

Main table

	Cumulative number of suspected acute respiratory infection outbreaks by type of educational setting for the 2021/22 academic year from Week 35 2021										
PHE Centres	Nursery	Primary School	Secondary School	Combined	Special Educational Needs (SEN) schools	College University	Total				
East Midlands Centre	72 (0)	59 (0)	30 (0)	14 (0)	163 (0)	6 (0)	344 (0)				
East of England Centre	0 (0)	12 (0)	8 (0)	3 (0)	11 (0)	2 (0)	36 (0)				
London Centre	365 (0)	1085 (0)	260 (0)	59 (0)	209 (0)	30 (0)	2008 (0)				
North East Centre	0 (0)	2 (0)	0 (0)	0 (0)	3 (0)	0 (0)	5 (0)				
North West Center	11 (0)	31 (0)	13 (0)	4 (0)	123 (0)	7 (0)	189 (0)				
South East Centre	42 (0)	389 (0)	127 (0)	34 (0)	287 (0)	7 (0)	886 (0)				
South West Centre	5 (0)	64 (0)	79 (0)	37 (0)	247 (0)	1 (0)	431 (0)				
West Midlands Centre	18 (0)	73 (0)	52 (0)	7 (0)	140 (0)	6 (0)	296 (0)				
Yorkshire & the Humber	17 (0)	36 (0)	27 (0)	5 (0)	81 (0)	0 (0)	166 (0)				
Total	530 (0)	1751 (0)	596 (0)	161 (0)	1264 (0)	59 (0)	4361 (0)				

* Number of acute respiratory infection for the most recent week in brackets




Secondary Care surveillance



14 June 2022



Weekly admission rates for hospital and ICU/HDU laboratory confirmed COVID-19 cases reported through SARI Watch, week 22




Source: PHE SARI-Watch (Severe Acute Respiratory Infection-Watch, formerly CHESS).

*Only NHS Acute trusts that have reported <u>>1</u> day in the past week; excludes Specialist trusts. Acute NHS trusts (including Specialist trusts) reporting into SARI-Watch COVID-19 hospitalisation surveillance are typically around 100 per week. This was 92 for the hospitalisation (all levels of care) indicator in week 30 May 2022 to 05 June inclusive and 81 trusts for the ICU/HDU indicator. For the maps, as Specialist trusts are excluded, the number of trusts providing data on COVID-19 hospitalisations in week ending 05 June 2022 was 86 and 75 for ICU/HDU admissions for COVID-19.

Age/sex pyramid of hospitalisations (all levels of care) for COVID-19, data UK Health from sentinel acute NHS trusts, England Security Agency

(a) Peak of 2nd wave (week 53 2020 to week 3 2021) n= 6,359



Reporting trusts=22

Reporting trusts=12

to 22 2022) n= 616

(b) Most recent 4 weeks (week 19 2022)


This figure is based on individual patient level data which are provided to SARI Watch from a subset of NHS Acute Trusts, therefore the data should be interpreted with caution as the distribution of age, sex and ethnic group may not be representative of all hospitalised patients.


■ Male ■ Female



Age/sex pyramid for admissions to ICU/HDU for COVID-19, mandatory case level data, acute NHS trusts, England UK Health Security Agency

(a) Peak of 2nd wave (week 53 2020 to week 3 2021) n= 3,349





This figure is based on individual patient level data which are provided to SARI Watch from a subset of NHS Acute Trusts, therefore the data should be interpreted with caution as the distribution of age, sex and ethnic group may not be representative of all hospitalised patients.




Laboratory confirmed admissions for COVID-19, to acute NHS trusts, by level UK Health of care and ethnicity

Security Agency

> (a) Peak of 2nd wave (week 53 2020 to week 3 2021)

(b) Most recent 4 weeks (week 19 2022 to 22 2022)




This figure is based on individual patient level data which are provided to SARI Watch from a subset of NHS Acute Trusts, therefore the data should be interpreted with caution as the distribution of age, sex and ethnic group may not be representative of all hospitalised patients.

Caveat: From week 24 2021 the ethnicity analysis is based on a new method for assigning ethnicity, developed by UKHSA. The previous method used the most recent ethnicity recorded through linkage to Hospital Episode Statistics. However, this method led to unfeasibly high rates in the 'Other' ethnic group when applied to COVID-19 cases, hospitalisation or mortality. The new method uses the most frequent ethnicity recorded through linkage to Hospital Episode Statistics, unless the most frequent was 'Other' when the second most frequent was chosen.

UK Health Security Agency

Weekly COVID-19 hospitalisation rate per 100,000 trust catchment population by age group and region, weeks 13 to 22




14 June 2022

•65 to 74


-75 to 84



Hospital admission rate (excluding ICU/HDU) by ethnicity per 100,000 trust catchment population



Caveat: From week 24 the ethnicity analysis is based on a new method for assigning ethnicity, developed by UKHSA. The previous method used the most recent ethnicity recorded through linkage to Hospital Episode Statistics. However, this method led to unfeasibly high rates in the 'Other' ethnic group when applied to COVID-19 cases, hospitalisation or mortality. The new method uses the most <u>frequent</u> ethnicity recorded through linkage to Hospital Episode Statistics, unless the most frequent was 'Other' when the second most frequent was chosen.



Caveat: From week 24 the ethnicity analysis is based on a new method for assigning ethnicity, developed by UKHSA. The previous method used the most recent ethnicity recorded through linkage to Hospital Episode Statistics. However, this method led to unfeasibly high rates in the 'Other' ethnic group when applied to COVID-19 cases, hospitalisation or mortality. The new method uses the most frequent ethnicity recorded through linkage to Hospital Episode Statistics, unless the most frequent was 'Other' when the second most frequent was chosen.

Week Number

Black Mixed

9 111315171921232527293133353739414345474951 1 3 5 7 9 111315171921

Other

7

_

Asian


4.00

2.00

0.00

121416182022242628303234363840424446485052 1 3 5

White



Notes

1) Case-level sentinel data from week 35 2021 (commencing 30 August 2021) to week 19 2022 (ending 15 May 2022) incl

2) Total 21,605 records in period of analysis, of which 40% (n=8538) had COVID-19 as primary reason for admission ('Yes').

3) SARS-CoV-2 patients with evidence of COVID-19 treatment but have 'No' or 'Unknown' for COVID-19 as primary reason for admission (n=619) are reassigned to COVID as primary reason of admission ('Yes').

4) Reassignment increases COVID-19 as primary reason for admission ('Yes') from 8538 to 9157

- 5) 21% (4523/21605) of total records in this period have missing data on the 'Admission due to COVID-19' indicator these are excluded from analysis
- 6) London trusts under-represented

14 June 2022




Mortality surveillance

Ś

UK Health

Security Agency Cumulative mortality rate of COVID-19 cases per 100,000 population tested under Pillar 1 and 2 since the beginning of the pandemic by 28 day definition





Co/secondary infections with COVID-19



Security Agency

Co/secondary infections with COVID-19

- Caveat undertesting for other pathogens may result in an underestimate of co/secondary infection cases.
- Preceding/co-/secondary infections refers to when a patient has a COVID-19 infection with one or more other pathogen (Please see Appendix 1 – Pre-/co-/secondary infection with COVID-19 definitions.)
 - Preceding infection: COVID-19 acquired after another pathogen
 - Co-infection: COVID-19 and other pathogen acquired at the same time
 - Secondary infection: COVID-19 acquired before another pathogen
- Numbers of pre-/co-/secondary infection remain low across UKHSA surveillance systems.
- For patients with severe respiratory failure requiring Extra Corporeal Membrane Oxygenation (ECMO), analysis of data from five adult ECMO centres in England indicates that among patients with severe respiratory failure due to COVID-19, almost a third of these have co/secondary infections.
- Published data analysis from pandemic wave 1 (W-1) indicates increased mortality associated with COVID-19 and <u>influenza</u>, <u>key bacterial and fungal infections</u> and <u>invasive pneumococcal disease</u> (IPD) in comparison to patients without co/secondary infection.
- <u>Data analysis</u> from W-1 indicates that *Aspergillus* and *candidemia* cases have increased risk of mortality in comparison to patients without co/secondary infection.



UK Health Co/secondary infections among patients with severe respiratory failure requiring Extra Corporeal Membrane Oxygenation (ECMO) Agency

Analysis is based on cumulative data from five adult ECMO centres in England. Data for the current and previous seasons are presented. Each season commences around October (ISO week 40) ending in September in the following year (ISO week 39).

Data for the current season (2021-22) is from 4 October 2021 to 15 May 2022 inclusive (week 40 2021 to week 19 2022). This period includes effects from the Delta and Omicron waves of the pandemic. The 2020-21 season is from 28 September 2020 to 3 October 2021 inclusive and includes effects from the Alpha and Delta waves. The 2019-20 season is from 30 September 2019 to 27 September 2020 inclusive and includes effects from the original Wuhan strain.

- In the 2021-22 season, 41% (31/76) of ECMO patients admitted for severe respiratory failure due to laboratory confirmed COVID-19 had clinically significant co/secondary infections. In the previous season (2020-21) this proportion was 30% (134/402). In the 2019-20 season this proportion was 33% (79/236).
- In all three seasons the majority of clinically significant co/secondary infections among respiratory failure COVID-19 cases comprised Gram-negative bacilli from the order Enterobacterales:
 - 45% (14/31) in the current season 2021-22
 - 32% (43/134) in 2020-21 and 46% (36/79) in 2019-20. The decrease in 2020-21 compared to 2019-20 reached borderline significance (p=0.057). (In the last data assessment, the decrease over this period was statistically significant but since then there were further updates to the data from ECMO centres). No change was detected in other key pathogens between these two time periods.



Surveillance of bacterial, fungal and viral infections, in COVID-19 patients in England, Jan 2020 – May 2022

HCAI, Fungal, AMR, AMU & Sepsis Division



Updates

- From 31 January 2022, UKHSA has changed the COVID-19 case definition to include multiple infection episodes. Reported co-/secondary/preceding infections in England now use the new definition, revising all cases back to the beginning of the pandemic.
- The Unified Infection Dataset (UID) project has been extended to incorporate the Co- and Secondary infections with COVID-19 datasets
- The following outputs included in this section have been produced via the UID, combining previously separate data pipelines
 - Key HCAI bacterial and fungal specimens reported to SGSS and HCAI data capture system
 - Respiratory viral specimens reported to SGSS and Respiratory Datamart
 - Fungal specimens reported to mycology reference lab (MRL)
- The Co- and secondary infections team have undertaken an extensive data validation exercise which has identified additional respiratory viral specimens from Respiratory Datamart and allowed us to make improvements to the methodologies. Preceding infections for all pipelines (other pathogen infections occurring before COVID-19 specimen) are now included. Please note, all cases since January 2020 have been revised in line with this validation.
- Data are provisional and subject to change due to possible delayed reporting of microbiological samples

UK Health Security Agency

Number of COVID-19 patient-episodes with bacterial, fungal or viral infections in COVID-19 patients diagnosed in England during wave 3*, by infection type and timing of diagnosis

Destavial for call visal infaction by	COVID-19 patient- episodes with bacterial/ fungal/ viral infection		Timing of bacterial/fungal/viral diagnosis in relation to COVID-19 diagnosis								
Bacterial/ fungal/ viral infection by specimen type			Preceding infection		Coinfection			Secondary infection			
	n	% of COVID cases	n	% infections by site	% of COVID cases	n	% infections by site	% of COVID cases	n	% infections by site	% of COVID cases
Bacterial/fungal bloodstream & lower respiratory infection	251	<0.01	22	8.76	<0.01	8	3.19	<0.01	221	88.05	<0.01
Bacterial/fungal bloodstream infection	7,867	0.05	3,342	42.48	0.02	1,535	19.51	0.01	2,990	38.01	0.02
Bacterial/fungal lower respiratory infection	2,550	0.02	591	23.18	<0.01	232	9.10	<0.01	1,727	67.73	0.01
Clostridioides difficile infection	1,032	0.01	408	39.53	<0.01	103	9.98	<0.01	521	50.48	<0.01
Fungal respiratory/bloodstream infection (MRL) [‡]	198	<0.01	14	7.07	<0.01	3	1.52	<0.01	181	91.41	<0.01
Other respiratory virus infection	2,816	0.02	790	28.05	0.01	1,295	45.99	0.01	731	25.96	<0.01
Any site†	14,751	0.10	5,179	35.11	0.04	3,177	21.54	0.02	6,395	43.35	0.04

Please see appendix 1 for pre-/co-/secondary infection definitions with SARS-CoV-2

Please note patients can have multiple COVID-19 infection-episodes, numbers here do not reflect the number of patients.

*SARS-CoV2 specimen dates from 27 Apr 2021 to 01 May 2022 (N=14,627,154). Last updated 06 Jun 2022.


[‡] Definition for secondary infection differs for MRL specimens - detection within 60 days


† includes the combination Bacterial/fungal bloodstream & *Clostridioides difficile* infection (12 preceding, 1 coinfection & 20 secondary), Bacterial/fungal bloodstream, lower respiratory & *Clostridioides difficile* infection (1

secondary), & Bacterial/fungal lower respiratory & Clostridioides difficile infection (3 secondary)

Key findings:

- 0.10% of COVID-19 patient-episodes had a bacterial, fungal or other respiratory viral infection detected in either the 28 days prior or following (60 days following for MRL) their COVID-19 diagnosis
- Prevalence in W3 lower than W2 and W1; however, patient-episodes of COVID-19 and another key infection are still higher in W3 than W1 (14,751 vs 4,636, respectively)
- The majority of infections with key organisms were categorised as secondary infections (43.35%).






Key findings:


In wave 3, the most frequent bacterial/fungal organisms identified from blood specimens were *Escherichia coli*, *Staphylococcus aureus* and *Klebsiella pneumoniae* and from respiratory specimens were *Staphylococcus aureus*, *Pseudomonas aeruginosa* and *Klebsiella pneumoniae*.

UK Health Security Agency

Most frequent viral specimens, by timing of diagnosis, in COVID-19 patients diagnosed in England during wave 3



UK Health Most frequent fungal species (MRL), by timing of diagnosis, in COVID-19 patients diagnosed Security in England during wave 3 Agency





Agency

UK Health COVID-19 co/secondary infection with fungi and vaccine preventable bacteria Security

First Wave Second Wave Third Wave Bacteria/Fungi Total Cases (1 May 2021 - 24 (29 June 2020 - 30 April 2021) (30 Jan 2020 - 28 June 2020) February 2022) Aspergillus fumigatus isolates (azole 46 (4) 120 (2) 137 (12) 303 (18) resistant) Probable/Proven cases of CAPA* 97 15 38 44 Candida spp.: Candidemia 63 133 17 213 Bordetella pertussis 0 0 0 0 Haemophilus influenzae 3 2 0 5 Neisseria meningitidis 2 0 0 2 Streptococcus pneumoniae 40 45 14 99

*COVID-19-associated pulmonary aspergillosis

Please note fungal data refers to secondary infections only. Mycology data contains results from Mycology reference laboratory data, Candidaemia is representative of deep infection. One case of osteomyelitis, one case of ventriculitis and one case of endocarditis was documented in wave two. Fungal data are also included in the overall numbers in slides 6-8 but have been stratified here with additional details. *Bordetella pertussis* co-infection is defined as +/- 28 d Culture/PCR (based on pertussis sample date), +/- 28 Serology/Oral fluid (anti-pertussis toxin Ig) (based on pertussis symptom onset date, excluding cases without onset date). *Haemophilus influenzae*, *Neisseria meningitidis* and *Streptococcus pneumoniae* co-infection is defined as +/- 2d. *Legionella*, *Mycoplasma* and gastrointestinal infection data not included. Please note, testing in W1 was not open to the community and therefore W1 cases are predominantly hospitalised patients vs. W2 and W3.

Appendix 1: Pre-/co-/secondary infection definitions with COVID-19

The day pertains to the date of the sample collection that yielded a positive result. These definitions do not apply to persistent COVID-19 patients. Patients with persistent COVID-19 require independent clinical assessment.

		Definition of infection pre-SARS-CoV-2 infection (other pathogen is primary infection)
Organism	Definition co-infection with SARS-CoV-2 †	or
		Definition of post SARS-CoV-2 secondary infection (SARS-CoV-2 is primary infection)
Influenza A	+/- 1d	2-28d^
Influenza B	+/- 1d	2-28d^
RSV	+/- 1d	2-28d
Adenovirus	+/- 1d	2-28d
Enterovirus	+/- 1d	2-28d
Human metapneumovirus	+/- 1d	2-28d
Parainfluenza (any subtype)	+/- 1d	2-28d
Seasonal coronavirus	+/- 1d *	2-28d
Rhinovirus	+/- 1d	2-28d
Co-infections in ECMO patient (patients w	ith most severe clinical respiratory signs)	
ECMO patients	Individual case review	Individual case review
Blood stream and respiratory infections (b	acterial and fungal)	
Achromobacter xylosoxidans	+/- 1d	2-28d
Acinetobacter spp.,	+/- 1d	2-28d
Aspergillus	+/- 1d	2-28d (pre) 2-60d (post, continually hospitalised patients only)
Bordetella pertussis	+/- 28 d Culture/PCR (based on pertussis sample	N/A (Pertussis presentation is often delayed)
	date)	
	+/- 28 Serology/Oral fluid (anti-pertussis toxin lg)	
	(based on pertussis symptom onset date, excluding	
	cases without onset date)	
Burkholderia cepacia	+/- 1d	2-28d
Candida spp	+/- 1d	2-28d (pre) 2-60d (post, continually hospitalised patients only)
Chlamydia pneumoniae	0-7d PCR	PCR within 14-28 d (8-13d PCR*)
Enterobacter spp.,	+/- 1d	2-28d
Enterococcus spp.	+/- 1d	2-28d
E. coli	+/- 1d	2-28d
Haemophilus influenzae	+/- 2d	3-28d

Appendix 1 continued: Pre-/co-/secondary infection definitions with COVID-19

The day pertains to the date of the sample collection that yielded a positive result. These definitions do not apply to persistent COVID-19 patients. Patients with persistent COVID-19 require independent clinical assessment.

Organism	Definition co-infection with SARS-CoV-2 †	Definition of infection pre-SARS-CoV-2 infection (other pathogen is primary infection) or
		Definition of post SARS-CoV-2 secondary infection (SARS-CoV-2 is primary infection)
Blood stream and respiratory infections (b	pacterial and fungal)	
Klebsiella spp.	+/- 1d	2-28d
Legionella pneumophila/species	Individual case review	Individual case review
Mycoplasma pneumoniae	0-7d PCR, IgM serology 0-21d <16y	PCR within 14-28 d (8-13d PCR*)
Neisseria meningitidis	+/- 2d	3-28d
Pseudomonas spp.,	+/- 1d	2-28d
Serratia spp.,	+/- 1d	2-28d
Staphylococcus aureus	+/- 1d	2-28d
Coag-neg Staphylococcus (S. haemolyticus)	+/- 1d	2-28d
Stenotrophomonas spp., (S. maltophilia)	+/- 1d	2-28d
Streptococcus spp. ‡	+/- 1d	2-28d
Streptococcus pneumoniae	+/- 2d	3-28d
Tuberculosis		
Mycobacterium tuberculosis	Individual case review	Individual case review
Pathogens of the immunocompromised (e	eg HIV)	
HIV	Individual case review	Individual case review
Gastrointestinal infections		
Listeria	0-5d *	Individual case review
Campylobacter	0-5d *	Individual case review
Shiga toxin-producing E. coli (STEC)	0-5d *	Individual case review
Norovirus	0-5d *	Individual case review
Salmonella	0-5d *	Individual case review
Shigella	0-5d *	Individual case review
Anaerobes		
C. difficile	+/- 1d	2-28d
Bacteroides sp. (<i>B. fragilis</i> and non- fragilis Bacteroides)	+/- 1d	2-28d

Appendix 1 continued: Pre-/co-/secondary infection definitions with COVID-19

Notes

† From SARS-CoV-2 first detection date. Not including multiple episodes of SARS-CoV-2 per patient.

* Additional data check required. (Resistance is not detailed, data for MERS is not currently available).

 ^ Definition post- SARS-CoV-2 secondary infection (SARS-CoV-2 is primary infection). This has been extended from prior 14d secondary infection definition for influenza used by PHE to account for disparities in testing throughout the 28d period after SARS-CoV-2 detection.
 ‡ Streptococcus species includes the following groups and species:

Group	Species/other names
Anginosus Group	Streptococcus anginosus; Streptococcus constellatus (Streptococcus constellatus subspecies constellatus Streptococcus
	constellatus subspecies pharynges); Streptococcus Group F; Streptococcus intermedius; Streptococcus milleri group;
	Streptococcus sinensis
Bovis Group	Streptococcus alactolyticus; Streptococcus bovis untyped; Streptococcus equinus; Streptococcus gallolyticus subspecies
	gallolyticus (Streptococcus bovis biotype I); Streptococcus infantarius (Streptococcus infantarius sp infantarius; Streptococcus
	bovis biotype II); Streptococcus lutetiensis; Streptococcus infantarius subspecies coli (Streptococcus bovis biotype II);
	Streptococcus pasteurianus (Streptococcus bovis biotype II)
Closely Related Genera	Abiotrophia spp.; Aerococcus spp.; Faklamia spp.; Gemella spp.; Globicatella sanguinis; Granulicatella spp.; Leuconostoc
	spp.; Pedicoccus spp.; Peptostreptococcus spp.
Mitis Group	Streptococcus cristatus; Streptococcus mitior; Streptococcus mitis; Streptococcus oralis; Streptococcus pseudopneumoniae;
	Streptococcus infantis; Streptococcus peroris
Mutans Group	Streptococcus mutans; Streptococcus sobrinus
Other streptococci (including but not	Anaerobic streptococcus; Streptococcus acidominimus; Streptococcus spp., other named/not fully identified; Streptococcus
limited to)	suis; Streptococcus uberis
Salivarius Group	Streptococcus vestibularis; Streptococcus thermophilus
Sanguinis Group	Streptococcus gordonii; Streptococcus massiliensis; Streptococcus parasanguinis; Streptococcus sanguinis
Streptococcus Group A	Group A; Streptococcus pyogenes; Streptococcus dysgalactiae subspecies equisimilis
Streptococcus Group B	Group B; Streptococcus agalactiae
Streptococcus Group C	Group C; Streptococcus dysgalactiae subspecies equisimilis; Streptococcus equi subspecies zooepidemicus
Streptococcus Group G	Group G; Streptococcus canis; Streptococcus dysgalactiae subspecies equisimilis